Pharma Industry News

US approves Lilly/Incyte’s Olumiant

As expected, US regulators have approved the lower dose of Eli Lilly/Incyte’s once-daily JAK inhibitor Olumiant as treatment for rheumatoid arthritis (RA).Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]